Search
Login
Register
Menu
Last issue
Home
News
CongressUpdate
Guidelines
Specials
Links
Reimbursement News
All
All
BJH articles
Blog articles
Specials
Search
Forgot Password?
Not a member yet? Register here
Home
/
General
/ Article: The best of ASH 2017
“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart.
View cart
Article: The best of ASH 2017
€
3.03
Article: The best of ASH 2017 quantity
Add to cart
SKU:
product-article-14468
Category:
General
Description
Description
The best of ASH 2017
Related products
Article: INTRODUCTION
€
3.03
Add to cart
Article: Highlights in squamous cell carcinoma of the head and neck
€
3.03
Add to cart
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€
3.03
Add to cart
Article: Highlights in breast cancer
€
3.03
Add to cart
Notifications